CANbridge Pharmaceuticals Inc. (1228.HK) HKSE

2.01

-0.08(-3.83%)

Updated at June 03 03:50PM

Currency In HKD

Key Executives

Name	Title	Pay	Year Born
Qun Xue	Founder, Chairman of the Board, Chief Executive Officer & Member of Strategic Advisory Board	3.91M	1970
Chris Chen	Senior Vice President of Human Resources	0	N/A
Joe Shen	Chief Operating Officer	0	N/A
Lillian Zhang	Senior Director & Head of Finance Operations and Controller	0	N/A
Rebecca Zhang	Chief Regulatory Advisor	0	N/A
Will Wang	Executive Director of Production	0	N/A
Qian Ma	Vice President, Company Secretary & General Counsel	0	N/A
Jeff Kou	Head of Clinical Operations and Senior Director of R&D Strategy & Portfolio Management	0	N/A
Suya Gao	Acting Head of Commercial Operations of Mainland China	0	N/A
Jason West	Head of Global Gene Therapy Research	0	N/A
Gerald F. Cox	Chief Development Strategist & Interim Chief Medical Officer	0	1959

Name

Title

Pay

Year Born

Qun Xue

Founder, Chairman of the Board, Chief Executive Officer & Member of Strategic Advisory Board

3.91M

1970

Chris Chen

Senior Vice President of Human Resources

N/A

Joe Shen

Chief Operating Officer

N/A

Lillian Zhang

Senior Director & Head of Finance Operations and Controller

N/A

Rebecca Zhang

Chief Regulatory Advisor

N/A

Will Wang

Executive Director of Production

N/A

Qian Ma

Vice President, Company Secretary & General Counsel

N/A

Jeff Kou

Head of Clinical Operations and Senior Director of R&D Strategy & Portfolio Management

N/A

Suya Gao

Acting Head of Commercial Operations of Mainland China

N/A

Jason West

Head of Global Gene Therapy Research

N/A

Gerald F. Cox

Chief Development Strategist & Interim Chief Medical Officer

1959

Description

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.